Fulgent Genetics (FLGT) Scheduled to Post Quarterly Earnings on Friday

Fulgent Genetics (NASDAQ:FLGT) will be posting its quarterly earnings results before the market opens on Friday, November 8th. Analysts expect Fulgent Genetics to post earnings of ($0.19) per share for the quarter. Individual interested in registering for the company’s earnings conference call can do so using this link.

Fulgent Genetics (NASDAQ:FLGT) last posted its earnings results on Friday, August 2nd. The company reported $0.15 EPS for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.45. The company had revenue of $71.03 million for the quarter, compared to the consensus estimate of $69.07 million. Fulgent Genetics had a negative return on equity of 2.75% and a negative net margin of 56.22%. Fulgent Genetics’s quarterly revenue was up 4.7% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.33) earnings per share. On average, analysts expect Fulgent Genetics to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Fulgent Genetics Stock Performance

FLGT opened at $21.45 on Friday. The business’s fifty day moving average is $21.20 and its two-hundred day moving average is $21.39. The company has a market cap of $641.87 million, a price-to-earnings ratio of -3.85 and a beta of 1.50. Fulgent Genetics has a one year low of $18.76 and a one year high of $30.68.

Insiders Place Their Bets

In other news, CEO Ming Hsieh sold 2,313 shares of the business’s stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $22.83, for a total value of $52,805.79. Following the completion of the transaction, the chief executive officer now directly owns 707,275 shares of the company’s stock, valued at $16,147,088.25. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Over the last ninety days, insiders have sold 4,324 shares of company stock worth $98,717. 31.76% of the stock is owned by corporate insiders.

About Fulgent Genetics

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.